Incidence of antibiotic-resistant Escherichia coli bacteriuria according to age and location of onset: A population-based study from Olmsted County, Minnesota

Mayo Clinic Proceedings

Volumn 87, Issue 8, 2012, Pages 753-759

  Swami, Sanjeev K ^a   Liesinger, Juliette T ^b   Shah, Nilay ^b   Baddour, Larry M ^b   Banerjee, Ritu ^b  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; GENTAMICIN; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BACTERIURIA; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GEOGRAPHY; GERIATRIC PATIENT; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MICROBIAL GROWTH; NONHUMAN; ONSET AGE; POPULATION RESEARCH; PRESCHOOL CHILD; PREVALENCE; SCHOOL CHILD; UNITED STATES; URINE CULTURE;

EID: 84866410554     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.02.025     Document Type: Article

References (46)

1. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis. 2010;51(3):286-294.
2. Johnson JR, Menard M, Johnston B, Kuskowski MA, Nichol K, Zhanel GG. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother. 2009;53(7):2733-2739.
3. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother. 2011;66(1):1-14.
4. Cagnacci S, Gualco L, Debbia E, Schito GC, Marchese A. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST 131 and O15:K52:H1 causing communityacquired uncomplicated cystitis. J Clin Microbiol. 2008;46(8):2605-2612.
5. Nicolas-Chanoine M-H, Blanco J, Leflon-Guibout V. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother. 2008;61(2):273-281.
6. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M-beta lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents. 2009;35(4):316-321.
7. de Kraker ME, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med. 2011;8(10):e1001104.
8. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49(8):1175-1184.
9. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32(8):1162-1171. (Pubitemid 32390110)
10. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum β-lactamase (ESBL) producing E.coli compared to non-ESBL producing E. coli. J Infect. 2007;55(3):254-259. (Pubitemid 47244918)
11. Peralta G, Blanca Sanchez M, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother. 2007;60(4):855-863. (Pubitemid 47434266)
12. Livermore D, Canton R, Gniadkowski M, Nordmann P, Rossolini G. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007;59(2):165-174. (Pubitemid 47072053)
13. Rodriguez-Bano J, Alcala J, Cisneros J, Grill F, Oliver A. Escherichia coli producing SHV-type extended-spectrum beta lactamase is a significant cause of community-acquired infection. J Antimicrob Chemother. 2009;63(4):781-784.
14. Smith SP, Manges AR, Riley LW. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition. Clin Infect Dis. 2008;46(5):689-695. (Pubitemid 351321552)
15. Rattanaumpawan P, Tolomeo P, Bilker WB, Fishman NO, Lautenbach E. Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections. J Hosp Infect. 2010;76(4):324-327.
16. Blaschke AJ, Korgenski EK, Daly JA, LaFleur B, Pavia AT, Byington CL. Extended-spectrum beta-lactamase-producing pathogens in a children's hospital: a 5-year experience. Am J Infect Control. 2009;37(6):435-441.
17. Coque T, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Eurosurveillance. 2008;13(48):1-11.
18. Peirano G, Costello M, Pitout JD. Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. Int J Antimicrob Agents. 2010;36(1):19-23.
19. Zaoutis TE, Goyal M, Chu JH, et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics. 2005;115(4):942-949.
20. Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J Antimicrob Chemother. 2009;64(1):169-174.
21. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect. 2008;14(11):1041-1047. (Pubitemid 352748845)
22. US Census Bureau. Olmsted County QuickFacts. Vol 2011. Available at http://quickfacts.census.gov/qfd/states/27/27109.html. Accessed July 7, 2012.
23. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71(3):266-274.
24. Steckelberg JM, Melton LJ III, Ilstrup DM, Rouse MS, Wilson WR. Influence of referral bias on the apparent clinical spectrum of infective endocarditis. Am J Med. 1990;88(6):582-588. (Pubitemid 20192269)
25. Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137(10):791-797. (Pubitemid 35334450)
26. Laupland K, Ross T, Pitout J, Church D, Gregson D. Communityonset urinary tract infections: a population-based assessment. Infection. 2007;35(3):150-153. (Pubitemid 46932329)
27. Jackson LA, Benson P, Neuzil KM, Grandjean M, Marino JL. Burden of community-onset Escherichia coli bacteremia in seniors. J Infect Dis. 2005;191(9):1523-1529. (Pubitemid 40563365)
28. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel J. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000;10(8):509-515.
29. Ruben F, Dearwater S, Norden C, et al. Clinical infections in the noninstitutionalized geriatric age group: methods utilized and incidence of infections: The Pittsburgh Good Health Study. Am J Epidemiol. 1995;141(2):145-157.
30. Caljouw MAA, den Elzen WPJ, Cools HJM, Gussekloo J. Predictive factors of urinary tract infections among the oldest old in the general population: a population-based prospective follow-up study. BMC Med. 2011;9:57.
31. Smith PW, Seip CW, Schaefer SC. Microbiologic survey of long-term care facilities. Am J Infect Control. 2000;28(1):8-13. (Pubitemid 30120933)
32. Trick WE, Weinstein RA, DeMarais PL. Colonization of skilledcare facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc. 2001;49(3):270-276. (Pubitemid 32240293)
33. Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA. 2007;298(2):179-186. (Pubitemid 47057764)
34. Paschke AA, Zaoutis T, Conway PH, Xie D, Keren R. Previous antimicrobial exposure is associated with drug-resistant urinary tract infections in children. Pediatrics. 2010;125(4):664-672.
35. Leflon-Guibout V, Ternat G, Heym B, Nicolas-Chanoine MH. Exposure to co-amoxiclav as a risk factor for co-amoxiclavresistant Escherichia coli urinary tract infection. J Antimicrob Chemother. 2002;49(2):367-371. (Pubitemid 34162630)
36. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. J Antimicrob Chemother. 2001;47(6):781-787. (Pubitemid 32519826)
37. Saint S, Kaufman SR, Rogers MA. Condom versus indwelling urinary catheters: a randomized trial. J Am Geriatr Soc. 2006;54(7):1055-1061. (Pubitemid 43992541)
38. Terpenning MS, Bradley SF, Wan JY. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc. 1994;42(10):1062-1069. (Pubitemid 24309816)
39. Calbo E, Romani V, Xercavins M, et al. Risk factors for communityonset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother. 2006;57(4):780-783.
40. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis. 2001;33(1):89-94. (Pubitemid 32554508)
41. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother. 2002;46(8):2540-2545. (Pubitemid 34793461)
42. Manges AR, Johnson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med. 2001;345(14):1007-1013.
43. Moffett SE, Frazee BW, Stein JC, et al. Antimicrobial resistance in uncomplicated urinary tract infections in 3 California EDs [published online ahead of print July 28, 2011]. Am J Emerg Med. http://dx.doi.org/10.1016/j.ajem. 2011.05.008.
44. Lagace-Wiens PRS, Simner PJ, Forward KR, et al. Analysis of 3789 in-and outpatient Escherichia coli isolates from across Canada: results of the CANWARD 2007-2009 study. Diag Microbiol Infect Dis. 2011;69(3):314-319.
45. Shlaes DM, Gerding DN, John JF, et al. Society of Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997;25(3):584-599. (Pubitemid 127774277)
46. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-120.